Lenvatinib/Lenvatinib Beacon version drug information introduction

Lenvatinib/Lenvatinib (Lenvatinib) is a generic version produced by Beacon Pharmaceuticals Ltd. of Bangladesh. The drug is a legal international generic drug that strictly follows the production standards of the World Health Organization (WHO) and local drug regulatory agencies. Its main active ingredients are the same as the original drug. It is used for the treatment of renal cell cancer, hepatocellular carcinoma, thyroid cancer, endometrial cancer and other diseases.

As a small molecule multi-target tyrosine kinase inhibitor, Bican version of lenvatinib can also inhibit a variety of signaling pathways related to tumor growth, including targets such as VEGFR, FGFR, PDGFRα, RET and KIT, thereby effectively blocking the angiogenesis and spread of tumors. This version of the drug is widely used in many overseas countries and regions, especially in countries with limited medical resources or expensive original drugs. The emergence of generic drugs has significantly improved patient affordability.

Currently, the common specifications of Becan’s version of lenvatinib are4mg, 10mg, etc. Different packaging dosage forms are suitable for patients at different treatment stages. Its market price is usually between RMB 400 and RMB 900 (which may vary slightly due to exchange rate fluctuations). Compared with the original drug, which often costs tens of thousands of yuan, it has obvious economic advantages. Although generic drugs are consistent with the original drugs in terms of ingredients and dosage design, it is still recommended to follow the guidance of a doctor when using them to ensure safety and efficacy.

In addition, Beacon Pharmaceutical maintains a high level of pharmaceutical quality management system, adopts advanced production equipment and quality inspection systems, and its products have obtained import approvals from many countries. Overall, the launch of Becan's version of lenvatinib provides a new treatment option for patients with limited financial conditions, making targeted therapy no longer a high burden and becoming a practical and accessible treatment approach.

Reference materials:https://www.lenvima.com/